# BPL-003

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/bpl-003
Canonical HTML page: https://getbiobrief.com/entity/bpl-003

## Timeline

- **2027-06-30**: Enrollment Milestone — Estimated completion of patient enrollment for the global Phase 3 study.
- **2026-04-01**: Phase 3 Launch Window — Expected start of the pivotal Phase 3 trial for Treatment-Resistant Depression.
- **2026-03-08**: Earnings & Timeline Release — Company announces 2025 results and sets Q2 2026 for BPL-003 Phase 3 launch.
- **2025-12-31**: FY 2025 Close — End of the fiscal year reporting period for AtaiBeckley.

## Recent coverage (2 stories)

### CareDx +35% on Medicare Win; Atai +33% on $3.8B Lilly Deal
2026-08-05 07:28:34 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

CareDx surged 35% after Medicare finalized coverage for transplant rejection tests, unlocking a major revenue opportunity. AtaiBeckley soared 33% following Eli Lilly's $3.8B acquisition, while Abbott raised its outlook and Apollomics extended its weekly rally to over 60% on its cancer drug candidate.
Full story: https://getbiobrief.com/story/caredx-atai-abbott-biotech-gainers-2026

### AtaiBeckley to Launch Phase 3 BPL-003 Trial Following Strong 2025 Results
2026-03-08 18:26:25 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

AtaiBeckley (ATAI) has confirmed the Q2 2026 launch of its Phase 3 program for BPL-003, an intranasal 5-MeO-DMT formulation for Treatment-Resistant Depression. The announcement follows the release of 2025 financial results that show a robust cash position capable of funding pivotal late-stage clinical development.
Full story: https://getbiobrief.com/story/ataibeckley-2025-results-bpl003-phase3-launch

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.